Strong Revenue Growth in Launch Products
Biogen's launch products demonstrated a year-on-year growth of 67% in Q3 2025, significantly offsetting the decline in MS revenue.
LEQEMBI Sales and Global Demand
LEQEMBI continues to show strong global demand with Q3 sales of $121 million and positive feedback from customers and payers.
Pipeline Progress
Litifilimab Phase III studies in SLE are fully enrolled with expected readouts in 2026, indicating strong commercial potential.
ZURZUVAE Revenue Growth
ZURZUVAE saw a 19% revenue growth compared to the previous quarter, driven by increased demand and new prescribers.
Financial Performance
Biogen delivered a 3% revenue growth overall, with non-GAAP diluted EPS growth of 18% and $1.2 billion in free cash flow in Q3 2025.